HCV Archives – Page 20 of 31 – Treatment Action Group

TAGline Spring 2015

April 8, 2015
Chad Cipiti

On Targets and Timelines: With growing recognition that science and discovery have forged the tools necessary to effectively diagnose, treat, and, indeed, eliminate three of the world’s most lethal infectious diseases—HIV/AIDS, tuberculosis, and hepatitis C—there is a need for greater mobilization and strengthened accountability among all stakeholders.

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

February 2, 2015
Chad Cipiti

Liver disease from hepatitis C virus (HCV) is one of the leading causes of death around the world. At least 185 million people have been infected and almost 500,000 people die from it each year. The hope for eradicating HCV has recently gained new momentum: effective treatments reaching a 100 percent cure rate in clinical trials are now available.

2014 TAG Update

December 11, 2014
Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

A Drug by Any Other Name

September 30, 2014
Chad Cipiti

The basics of generic medications, bioequivalence, and the push for good manufacturing practices Tim Horn Securing access to generic drugs to treat HIV, hepatitis C virus (HCV), and tuberculosis (TB) is now one of the most prominent strategies of global…

TAGline Fall 2014

September 30, 2014
Chad Cipiti

Hello Generics: A Drug by Any Other Name; The Road to Treatment Access; Safeguarding Against Stockouts; Generics vs. the Giant

Activists Hold Die-In to Protest High Price of Gilead’s Hepatitis C Drug

July 24, 2014
Chad Cipiti

Treatment activists at the 20th International AIDS Conference held a die-in to protest the exorbitant pricing of Sovaldi (sofosbuvir), Gilead’s new hepatitis C virus (HCV) drug. As Gregg Alton, Gilead’s Executive Vice President of Corporate and Medical Affairs, spoke, activists brought him a liver on a silver platter while chanting “Pills Cost Pennies, Greed Costs Lives,” “Shame, Shame, Shame,” and “Pharma Greed Kills.”

2014 Pipeline Report

July 18, 2014
Chad Cipiti

July 20, 2014 HIV, HCV, and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn…

1st Hepatitis C Virus World Community Advisory Board Report

July 11, 2014
Chad Cipiti

PILLS COST PENNIES, GREED COSTS LIVES July 14, 2014 By Odilon Couzin and Karyn Kaplan About the Hepatitis C Virus World Community Advisory Board Since the early years of the AIDS epidemic, people living with HIV/AIDS and their allies have…

New Hepatitis Resolution Is Passed at World Health Assembly; Challenges World Health Organization and Member States to Act

May 22, 2014
Chad Cipiti

Today, four years after introducing its first viral hepatitis resolution, the World Health Assembly (WHA)—the decision-making body of the World Health Organization (WHO)—passed the Hepatitis Resolution, which commits the WHO and United Nations (UN) member states to urgent action to address the global hepatitis pandemic, including that of hepatitis C virus (HCV).

Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C

May 16, 2014
Chad Cipiti

Position Paper for the 67th World Health Assembly, May 19–24, 2014 The World Health Organization (WHO) has referred to hepatitis C as a “viral time bomb.” In 2010, the 63rd World Health assembly (WHA) adopted the first resolution on viral…